GSK plc (LON:GSK) Receives GBX 2,055.71 Average PT from Brokerages

Shares of GSK plc (LON:GSK) have been assigned a consensus recommendation of “Hold” from the seven ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is GBX 2,034.29.

GSK has been the subject of several recent research reports. UBS Group reaffirmed a “neutral” rating and set a GBX 1,940 price target on shares of GSK in a report on Friday, January 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 1,900 price target on shares of GSK in a report on Wednesday. Berenberg Bank reaffirmed a “hold” rating and set a GBX 2,000 price target on shares of GSK in a report on Thursday, March 26th. Shore Capital Group reaffirmed a “buy” rating on shares of GSK in a report on Wednesday, March 25th. Finally, Citigroup decreased their price target on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a report on Wednesday.

GSK Price Performance

GSK stock opened at GBX 1,843 on Friday. The company has a market capitalization of £73.57 billion, a P/E ratio of 12.97, a PEG ratio of 1.24 and a beta of 0.30. GSK has a twelve month low of GBX 1,288.61 and a twelve month high of GBX 2,282. The business has a 50 day simple moving average of GBX 2,063.58 and a 200-day simple moving average of GBX 1,932.45. The company has a current ratio of 0.79, a quick ratio of 0.73 and a debt-to-equity ratio of 106.74.

GSK (LON:GSK) last posted its quarterly earnings data on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. The business had revenue of GBX 762.90 billion during the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%. As a group, equities analysts anticipate that GSK will post 175.980975 EPS for the current year.

Insider Buying and Selling

In other GSK news, insider Jonathan Symonds acquired 5,000 shares of the business’s stock in a transaction on Friday, March 20th. The stock was purchased at an average price of GBX 1,951 per share, for a total transaction of £97,550. Also, insider Anne Beal acquired 196 shares of the business’s stock in a transaction on Friday, March 20th. The stock was acquired at an average price of GBX 5,179 per share, with a total value of £10,150.84. Insiders bought 12,952 shares of company stock valued at $26,850,952 in the last ninety days. Company insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.